

EXPRESS MAIL: EL329909087US

PATENT

BOX SEQUENCE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Patent Application of Jürgen Eck et al. :  
Serial No.: Not Yet Assigned :  
Filed: Herewith :  
For: RECOMBINANT FUSION PROTEINS :  
BASED ON RIBOSOME-INACTIVATING: :  
PROTEINS OF THE MISTLETOE : Attorney Docket  
*VISCUM ALBUM* : No. **9282-5**  
(B3521 US)

**STATEMENT TO SUPPORT FILING AND SUBMISSION  
IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825**

- (X) I hereby state, in accordance with the requirements of **37 C.F.R. §1.821(f)**, that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 C.F.R. §1.821(c)** and **(e)**, respectively are the same.
- ( ) I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(g)** does not include new matter.
- ( ) I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- ( ) I hereby state that the amendments, made in accordance with **37 C.F.R. §1.825(a)**, included in the initial/substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages \_\_\_\_\_. I hereby state that the substitute sheets(s) of the Sequence Listing does(do) not include new matter.
- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(b)**, is the same as the amended Sequence Listing.

- ( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

**JÜRGEN ECK et al.**

July 2, 1999

(Date)

By: 

**GARY D. COLBY, Ph.D.**

Registration No. 40,961

**PANITCH SCHWARZE JACOBS & NADEL, P.C.**

One Commerce Square

2005 Market Street - 22nd Floor

Philadelphia, PA 19103-7086

Telephone: (215) 567-2020

**Direct Dial: (215) 965-1285**

Facsimile: (215) 567-2991

E-Mail: GDC@PSJN.com